A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients

Victoria Y. Yu, Angelia Landers, Kaley Woods, Dan Nguyen, Minsong Cao, Dongsu Du, Robert K. Chin, Ke Sheng, Tania B. Kaprealian

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To evaluate the feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort in the clinical implementation of 4π radiation therapy. Methods and Materials: Eleven patients with recurrent high-grade glioma were recruited for the trial. 4π plans integrating beam orientation and fluence-map optimization were created using an in-house column-generation algorithm. The collision-free beam solution space throughout the 4π steradian was determined using a computer-aided-design model of the Varian TrueBeam system and a human subject. Twenty beams were optimized for each case and imported into Eclipse for intensity modulated radiation therapy planning. Beam orientations with neighboring couch kicks were merged for increased delivery efficiency, generating plans with an average of 16 beam orientations. Volumetric modulated arc therapy (VMAT) plans with 3-4 arcs were also generated for each case, and the plan achieving superior dosimetric quality was selected for treatment. Patient comfort was surveyed after every fraction. Multiple 2-dimensional X-ray images were obtained to measure intrafractional motion. Results: Of 11 patients, 9 were treated with 4π. Mean and maximum organ at risk doses were equal or significantly lower (P <.05) with 4π than with VMAT. Particularly substantial dose reduction of 2.92 Gy in the average accumulated brainstem maximum dose enabled treatments that would otherwise not satisfy safe dose constraints with VMAT. One patient was not treated because neither plan met the dosimetric criteria. The other was treated with VMAT owing to comparable dosimetry resulting from a planning target volume located in a separate co-plane superior to organs at risk. Treatments were well tolerated, with an average patient comfort score of 8.6/10. Intrafractional motion was <1.5 mm for all delivered fractions, and the average delivery time was 34.1 minutes. Conclusions: The feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort of 4π radiation therapy have been clinically demonstrated with a prospective clinical trial. The results elucidate the potential and challenges of wider clinical implementations.

Original languageEnglish (US)
Pages (from-to)144-151
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume101
Issue number1
DOIs
StatePublished - May 1 2018

Fingerprint

Intensity-Modulated Radiotherapy
Glioma
radiation therapy
grade
Radiotherapy
Organs at Risk
comfort
arcs
Efficiency
therapy
delivery
dosage
Safety
Computer-Aided Design
organs
planning
safety
Brain Stem
Therapeutics
couches

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients. / Yu, Victoria Y.; Landers, Angelia; Woods, Kaley; Nguyen, Dan; Cao, Minsong; Du, Dongsu; Chin, Robert K.; Sheng, Ke; Kaprealian, Tania B.

In: International Journal of Radiation Oncology Biology Physics, Vol. 101, No. 1, 01.05.2018, p. 144-151.

Research output: Contribution to journalArticle

Yu, Victoria Y. ; Landers, Angelia ; Woods, Kaley ; Nguyen, Dan ; Cao, Minsong ; Du, Dongsu ; Chin, Robert K. ; Sheng, Ke ; Kaprealian, Tania B. / A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients. In: International Journal of Radiation Oncology Biology Physics. 2018 ; Vol. 101, No. 1. pp. 144-151.
@article{7c5271d8ca994de7a38fe58de84cb3d3,
title = "A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients",
abstract = "Purpose: To evaluate the feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort in the clinical implementation of 4π radiation therapy. Methods and Materials: Eleven patients with recurrent high-grade glioma were recruited for the trial. 4π plans integrating beam orientation and fluence-map optimization were created using an in-house column-generation algorithm. The collision-free beam solution space throughout the 4π steradian was determined using a computer-aided-design model of the Varian TrueBeam system and a human subject. Twenty beams were optimized for each case and imported into Eclipse for intensity modulated radiation therapy planning. Beam orientations with neighboring couch kicks were merged for increased delivery efficiency, generating plans with an average of 16 beam orientations. Volumetric modulated arc therapy (VMAT) plans with 3-4 arcs were also generated for each case, and the plan achieving superior dosimetric quality was selected for treatment. Patient comfort was surveyed after every fraction. Multiple 2-dimensional X-ray images were obtained to measure intrafractional motion. Results: Of 11 patients, 9 were treated with 4π. Mean and maximum organ at risk doses were equal or significantly lower (P <.05) with 4π than with VMAT. Particularly substantial dose reduction of 2.92 Gy in the average accumulated brainstem maximum dose enabled treatments that would otherwise not satisfy safe dose constraints with VMAT. One patient was not treated because neither plan met the dosimetric criteria. The other was treated with VMAT owing to comparable dosimetry resulting from a planning target volume located in a separate co-plane superior to organs at risk. Treatments were well tolerated, with an average patient comfort score of 8.6/10. Intrafractional motion was <1.5 mm for all delivered fractions, and the average delivery time was 34.1 minutes. Conclusions: The feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort of 4π radiation therapy have been clinically demonstrated with a prospective clinical trial. The results elucidate the potential and challenges of wider clinical implementations.",
author = "Yu, {Victoria Y.} and Angelia Landers and Kaley Woods and Dan Nguyen and Minsong Cao and Dongsu Du and Chin, {Robert K.} and Ke Sheng and Kaprealian, {Tania B.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2018.01.048",
language = "English (US)",
volume = "101",
pages = "144--151",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients

AU - Yu, Victoria Y.

AU - Landers, Angelia

AU - Woods, Kaley

AU - Nguyen, Dan

AU - Cao, Minsong

AU - Du, Dongsu

AU - Chin, Robert K.

AU - Sheng, Ke

AU - Kaprealian, Tania B.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose: To evaluate the feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort in the clinical implementation of 4π radiation therapy. Methods and Materials: Eleven patients with recurrent high-grade glioma were recruited for the trial. 4π plans integrating beam orientation and fluence-map optimization were created using an in-house column-generation algorithm. The collision-free beam solution space throughout the 4π steradian was determined using a computer-aided-design model of the Varian TrueBeam system and a human subject. Twenty beams were optimized for each case and imported into Eclipse for intensity modulated radiation therapy planning. Beam orientations with neighboring couch kicks were merged for increased delivery efficiency, generating plans with an average of 16 beam orientations. Volumetric modulated arc therapy (VMAT) plans with 3-4 arcs were also generated for each case, and the plan achieving superior dosimetric quality was selected for treatment. Patient comfort was surveyed after every fraction. Multiple 2-dimensional X-ray images were obtained to measure intrafractional motion. Results: Of 11 patients, 9 were treated with 4π. Mean and maximum organ at risk doses were equal or significantly lower (P <.05) with 4π than with VMAT. Particularly substantial dose reduction of 2.92 Gy in the average accumulated brainstem maximum dose enabled treatments that would otherwise not satisfy safe dose constraints with VMAT. One patient was not treated because neither plan met the dosimetric criteria. The other was treated with VMAT owing to comparable dosimetry resulting from a planning target volume located in a separate co-plane superior to organs at risk. Treatments were well tolerated, with an average patient comfort score of 8.6/10. Intrafractional motion was <1.5 mm for all delivered fractions, and the average delivery time was 34.1 minutes. Conclusions: The feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort of 4π radiation therapy have been clinically demonstrated with a prospective clinical trial. The results elucidate the potential and challenges of wider clinical implementations.

AB - Purpose: To evaluate the feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort in the clinical implementation of 4π radiation therapy. Methods and Materials: Eleven patients with recurrent high-grade glioma were recruited for the trial. 4π plans integrating beam orientation and fluence-map optimization were created using an in-house column-generation algorithm. The collision-free beam solution space throughout the 4π steradian was determined using a computer-aided-design model of the Varian TrueBeam system and a human subject. Twenty beams were optimized for each case and imported into Eclipse for intensity modulated radiation therapy planning. Beam orientations with neighboring couch kicks were merged for increased delivery efficiency, generating plans with an average of 16 beam orientations. Volumetric modulated arc therapy (VMAT) plans with 3-4 arcs were also generated for each case, and the plan achieving superior dosimetric quality was selected for treatment. Patient comfort was surveyed after every fraction. Multiple 2-dimensional X-ray images were obtained to measure intrafractional motion. Results: Of 11 patients, 9 were treated with 4π. Mean and maximum organ at risk doses were equal or significantly lower (P <.05) with 4π than with VMAT. Particularly substantial dose reduction of 2.92 Gy in the average accumulated brainstem maximum dose enabled treatments that would otherwise not satisfy safe dose constraints with VMAT. One patient was not treated because neither plan met the dosimetric criteria. The other was treated with VMAT owing to comparable dosimetry resulting from a planning target volume located in a separate co-plane superior to organs at risk. Treatments were well tolerated, with an average patient comfort score of 8.6/10. Intrafractional motion was <1.5 mm for all delivered fractions, and the average delivery time was 34.1 minutes. Conclusions: The feasibility, safety, dosimetric benefits, delivery efficiency, and patient comfort of 4π radiation therapy have been clinically demonstrated with a prospective clinical trial. The results elucidate the potential and challenges of wider clinical implementations.

UR - http://www.scopus.com/inward/record.url?scp=85044591381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044591381&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.01.048

DO - 10.1016/j.ijrobp.2018.01.048

M3 - Article

C2 - 29619962

AN - SCOPUS:85044591381

VL - 101

SP - 144

EP - 151

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -